Form 4: LifeMD COO Shayna Webb Dray to Receive 50,000 Restricted Stock Units

LifeMD's Chief Operating Officer, Shayna Webb Dray, is scheduled to acquire 50,000 restricted stock units, vesting over three years, which will increase her beneficial ownership to 265,000 shares.

Summary

• Shayna Webb Dray, Chief Operating Officer of LifeMD, Inc. (LFMD), is scheduled to acquire 50,000 shares of common stock.
• The acquisition is a grant of restricted stock units (RSUs) with a price of $0 per share, set to occur on July 27, 2025.
• These 50,000 restricted stock units will vest in tranches: 10,000 units on January 1, 2026; 20,000 units on January 1, 2027; and 20,000 units on January 1, 2028.
• Following this scheduled transaction, Ms. Dray's total beneficial ownership of LifeMD common stock will be 265,000 shares.

Sentiment

Score: 7

Explanation: The scheduled grant of restricted stock units to a key executive is generally a positive signal, indicating management's long-term commitment and alignment with shareholder interests. It's a standard compensation practice that reinforces confidence.

Positives

• The scheduled grant of 50,000 restricted stock units to the Chief Operating Officer indicates continued alignment of management incentives with long-term shareholder interests.
• The increase in beneficial ownership by a key executive demonstrates confidence in the company's future prospects and commitment to its long-term success.

Negatives

• The transaction is a grant of restricted stock units with a $0 price, meaning there is no immediate cash inflow from the executive's personal investment, unlike an open market purchase.

Future Outlook

The vesting schedule for the restricted stock units extends through January 2028, indicating a long-term incentive structure for the Chief Operating Officer and a commitment to future performance.

Industry Context

The grant of restricted stock units is a common practice in the healthcare technology and telehealth industry to align executive incentives with long-term company performance and shareholder value creation, especially in growth-oriented companies like LifeMD.

Comparison to Industry Standards

• Executive compensation through equity grants, particularly restricted stock units with multi-year vesting schedules, is a standard practice across publicly traded companies, including those in the digital health and pharmaceutical sectors.
• This aligns with typical incentive structures seen in companies like Teladoc Health (TDOC) or Hims & Hers Health (HIMS), where long-term retention and performance alignment are key components of executive compensation packages.

Stakeholder Impact

• Shareholders: Increased alignment of executive incentives with long-term share price performance and company growth.
• Employees: May signal stability and confidence in the company's leadership and future direction.

Next Steps

• 10,000 restricted stock units are scheduled to vest on January 1, 2026.
• 20,000 restricted stock units are scheduled to vest on January 1, 2027.
• 20,000 restricted stock units are scheduled to vest on January 1, 2028.

Key Dates

Recommendation

This Form 4 filing reports a standard executive compensation grant of restricted stock units, which aligns management incentives with long-term shareholder value. It does not provide new financial performance data or strategic shifts that would warrant a change in investment recommendation. It's a routine disclosure that reinforces a 'hold' stance for existing investors, as it indicates continued executive commitment without presenting a compelling new reason to buy or sell.

Keywords

LifeMD, LFMD, Shayna Webb Dray, Restricted Stock Units, RSU, Insider Ownership, Executive Compensation, SEC Form 4, Stock Grant, Chief Operating Officer